BSG and infection: Loss of CD147 not only reduced SARS-CoV-2 infection, but also significantly reduced cellular entry of BA.1 and BA.2 variants (Supplementary Fig. 12b), with reduced infection rates of 72.9%, 76.0% and 55.0%, respectively, indicating CD147 is still an entry receptor for Omicron variants.